A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer Article Early Access

Industry Collaboration International Collaboration

cited authors

  • Harding, James J.; Fan, Jia; Oh, Do-Youn; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; Bao, Lequn; Sun, Hui-Chuan; Macarulla, Teresa; Xie, Feng; Metges, Jean-Phillippe; Ying, Jie'er; Bridgewater, John; Lee, Myung-Ah; Tejani, Mohamedtaki A.; Chen, Emerson Y.; Kim, Dong Uk; Wasan, Harpreet; Ducreux, Michel; Bao, Yuanyuan; Lindsey, Stacie; Bachini, Melinda; Morement, Helen; Boyken, Lisa; Ma, Jiafang; Garfin, Phillip; Pant, Shubham; HERIZON BTC 01 Study Grp

authors

Publication Date

  • August 2, 2024

webpage

published in

category

keywords

  • Biliary tract cancer
  • HER2-positive
  • zanidatamab